Involvement of Innate and Adaptive Immunity in Parkinson's Disease

Central nervous system (CNS) was considered as an “immunologically privileged site”. However, accumulating evidence supports a role for neuro inflammation in progress in Parkinson’s disease (PD). Not only the activated resident microglia in brains, cytokine levels in CNS and blood, the presence of auto antibodies, and the infiltration of T-cell in CNS also contribute disease progression. The interplay between innate and adaptive immunity in the pathobiology of PD will be focused on this article.

• Publication year

  2017

• Venue

  Journal of Neurology and Stroke

• Publication date

  2017-01-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.15406/JNSK.2016.05.00188
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission

  2012cited by this paper
• Human leukocyte antigen variation and Parkinson's disease.

  2011cited by this paper
• Parkinson's Disease and Systemic Inflammation

  2011cited by this paper
• Multiple Loci Are Associated with White Blood Cell Phenotypes

  2011cited by this paper
• α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients

  2011cited by this paper
• Genome-wide association study confirms extant PD risk loci among the Dutch

  2011cited by this paper
• α-Synuclein Alters Toll-Like Receptor Expression

  2011cited by this paper
• Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease

  2010cited by this paper
• Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.

  2010cited by this paper
• Interleukin-1β contributes to dopaminergic neuronal death induced by lipopolysaccharide-stimulated rat glia in vitro.

  2010cited by this paper
• Association of the human leucocyte antigen region with susceptibility to Parkinson's disease

  2010cited by this paper
• Anti-melanin antibodies are increased in sera in Parkinson's disease.

  2009cited by this paper
• Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson’s Disease

  2009cited by this paper
• Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.

  2009cited by this paper
• Neuroinflammation in Parkinson's disease: a target for neuroprotection?

  2009cited by this paper
• Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease.

  2008cited by this paper
• The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery

  2008cited by this paper
• Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons

  2008cited by this paper
• Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease

  2008cited by this paper
• The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains.

  2008cited by this paper
• Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease

  2007cited by this paper
• Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys.

  2006cited by this paper
• Autoantibodies to alpha‐synuclein in inherited Parkinson’s disease

  2006cited by this paper
• In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease.

  2006cited by this paper
• Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra.

  2006cited by this paper
• The acute and the long‐term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation

  2005cited by this paper
• A possible role for humoral immunity in the pathogenesis of Parkinson's disease.

  2005cited by this paper
• Anti-neurofilament antibodies in blood of patients with neurological diseases

  2004cited by this paper
• Neurotoxic Effects of Lipopolysaccharide on Nigral Dopaminergic Neurons Are Mediated by Microglial Activation, Interleukin-1β, and Expression of Caspase-11 in Mice*

  2004cited by this paper
• Anti‐GM1 ganglioside antibodies in Parkinson's disease

  2002cited by this paper
• Role of Fcγ receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra

  2002cited by this paper
• The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system.

  2000cited by this paper
• Microglia as mediators of inflammatory and degenerative diseases.

  1999cited by this paper
• Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease

  1998cited by this paper
• Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1998cited by this paper
• Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis.

  1998cited by this paper
• Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

  1995cited by this paper
• Parkinson's disease and immunological abnormalities: increase of HLA‐DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood

  1994cited by this paper
• Neurodegenerative Disease: Autoimmunity Involving Calcium Channels a

  1994cited by this paper
• Anti-tau-positive glial fibrillary tangles in the brain of postencephalitic parkinsonism of Economo type.

  1993cited by this paper
• Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures.

  1990cited by this paper
• Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

  1988cited by this paper
• Immunocytochemical investigations on the presence of neuron-specific antibodies in the CSF of Parkinson's disease cases

  1988cited by this paper
• Antineurofilament antibodies in postencephalitic and idiopathic Parkinson's disease.

  1983cited by this paper

• No citing papers are available for this paper.